Physician profile
Nicholas Davakis
NPI 1730120205
$3,593.45
in general payments reported to CMS, 2019-2025
21 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $188 · 2021: $290 · 2022: $521 · 2023: $919 · 2024: $757 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,239.30 | 2022-2025 | Avvigo Guidance System, Opticross, Watchman Flx |
| Amgen INC. | $373.49 | 2019-2024 | Repatha |
| Novo Nordisk INC | $346.57 | 2023-2025 | Wegovy, Ozempic |
| Abiomed | $338.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $279.85 | 2019-2025 | |
| Medtronic, INC. | $161.23 | 2023-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Zoll Circulation INC | $150.00 | 2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Cardiovascular Systems INC. | $147.73 | 2019-2022 | |
| Abbott Laboratories | $109.23 | 2024 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $99.18 | 2024-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $88.95 | 2019-2023 | Farxiga, Brilinta |
| Pfizer INC. | $45.99 | 2024 | |
| Sanofi-Aventis U.S. LLC | $39.08 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $27.85 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $26.00 | 2021 | |
| Teleflex LLC | $19.89 | 2025 | Vascband |
| Kiniksa Pharmaceuticals, LTD. | $19.65 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.15 | 2023 | Lifevest |
| Biosense Webster, INC. | $16.50 | 2020 | |
| Cvrx, INC. | $9.70 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Davakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.